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ARSTRACT 
Molecular cloning technique was used to clone the EBV-specific 
DNase gene into pUC18 vector and transformed into E. coli JM105 starting 
from mRNA from B95-8 and Raji cell cultures. The fidelity of the cloning 
procedure from B95-8 was examined by deoxyribonucleotide sequencing by 
.. the Sanger's dideoxy sequencing method. Results showed that molecular 
cloning of the Epstein-Barr virus-specific DNase gene from the B95-8 cell 
culture had 100% fidelity . Comparison of the amino acid sequence of the N-
terminal end of the EBV DNase cloned from B95-8 and Raji Epstein-Barr 
Virus showed that they are conserved . Amino acid from 20-28 of the N-
terminal end of the Epstein-Barr virus-specific DNase protein is the functional 
domain of the protein and this part of the Epstein-Barr virus specific-DNase 
was included in the amino acid comparison described above. Results of DNA 
sequencing of the Epstein-Barr virus-specific DNase protein, from B95-8 and • ‘‘ -
Raji cell lines Epstein-Barr viruses is conserved. Comparison of the C-
terminal end of the Epstein-Barr virus-specific DNase protein showed 
nucleotide difference and resulted into two amino acid variations.. One of 
\ 
these variations converted a hydrophobic region of the B95-8 Epstein-Barr 
Virus-specific DNase protein to a hydrophiHc region of the Raji Epstein-Barr 
vims-specific DNase protein. 
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i 
. . 一 . . _ . , 
Hydrophilicity plot was run on the Epstein-Barr Virus speciflc-DNase 
synthetic peptides corresponding to hydrophilic regions were used as antigen 
in an enzyme - linked immunosorbent assay (ELISA) for the identification of 
immunological important linear epitopes using histologically proven 
nasopharyngeal carcinoma Q<^ PC) patients' sera with a peptide from Epstein-
Barr Virus Nuclear Antigen -1 (EBNA-1) as a positive control. Results 
. showed that none of the peptides，including the control EBNA-1 peptide， 
reacted with selected NPC sera. Results showed that the EBV-specific DNase 
protein may not have importnat linear epitopes and the major 
immunologically important epitope may be conformational i.e. depending on 
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CHAPTER 1: INTRODUCTION 
1.1. HISTORY 
The major events leading to the discovery of the Epstein-Barr virus (EBV) 
represented the . rapidly evolving nature of medical and scientific research <?f our 
time. The discovery of EBV was originated from the investigations on African 
-
Burkitt's lymphoma (BL), an unusual lymphoma bearing the name of the surgeon 
Denis Burkitt who had done extensive epidemiological work on this common 
. childhood tumor in Africa 1• Burkitt's lymphoma was found to be linked to the 
temperature and rainfall of the local areas where the tumor was prevalent. An 
infective nature of the tumor was suspected2• Collaborative work to look for a viral 
cause was initiated with Anthony Epstein and co-worker in England. Working on 
cell cultures originated from Burkitt's lymphoma, a herpesvirus was found to be 
reactivated in these cells3. The virus was shown to be serologically distinct from the 
other human herpesviruses and was unable to be cultivated in other cells known to 
be susceptible to the other herpesviruses. Upon the discovery of this unique virus, 
subsequently named as Epstein-Barr virus, an extensive amount of work was 
initiated by different laboratories to investigate this first evidence for ·a human 
tumor caused by a virus. 
Using the lymphoma cells as the basis for serological surveys in human 
populations, it was found that the bIajority of populations under study have 
antibodie~ to EBvA and that a serological relationship exis~ed with endemic BL in 
Africa and undifferentiated nasopharyngeal carcinoma (N1?C), a tumor which is 
common in southern Chinese populations but rarely seen in most other pop 
ulationss,6. The virus was also demonstrated to be the cause of infectious 
1 
mononucleosis (M) in the accidental finding that a technician in Henle's laboratory 
seroconverted to EBV while suffering from m \ 
While EBV was being identified as the cause of human diseases of many 
forms, the first evidence ofadirect pathogenic role ofEBV in human cancer arisen 
from report that EBV is capable of transforming human B lymphocytes and 
immortalizing these cells into linesl Such properties of EBV have been used 
widely as a method for the immortalizing lymphocytes for different studies. 
,1. 2. CLASSIFICATION AND STRUCTURE OF EBV 
EBV had been classified as a member ofthe family ofHerpesviridae and 
is used as the prototype virus for the Lymphocryptovirus genus. The host range of 
Lymphocryptovirus are restricted to old world primate species and EBV is the 
human Lymphocryptovirus. toi addition, the host range of these viruses in vitro is 
restricted to primate lymphocytes of the immunoglobulin-producing lineage (B 
lymphocytes) and these cell are the targets for latent infection in vivo\ 
The nucleic acid core of EBV is surrounded by an icosahedral capsid 
consisting of 162 capsomeres. This nucelocapsid measures about 100 nm in 
diameter. The nucleocapsid is surrounded by an irregular-shaped lipid-containing 
envelope which is derived from the membrane of the host cell as the virus buds 
through the cell membrane during the replication of the virus in susceptible cells^°" 
12. The major EBV capsid proteins are�160，47 and 28 kDa and are similar in size to 
the major herpes simplex virus type 1 capsid proteins: In addition to the major 
capsid proteins, there are a number of minor virion proteins. Unlike other 
herpesviruses, only one major glycoprotein is present in the outer viral envelope. 
,. 
I 
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The most abundant EBV envelope glycoprotein (or tegument protein) are of the 
sizes 350/220 or 152 kDa and differ in size to those ofthe other herpesviruses 14. 
1. 3. GENOMIC ORGANIZATION OF EPSTEIN-BARR VIRUS 
EBV is a double-stranded DNA virus with a linear DNA of 172 kbp 
kmgi5,i6 composed of 60 mole percent of guanine or cytosine residues. The 
characteristic features of the genomic organization of EBV consist of a single 
overall format and gene arrangement^ The other distinctive features of EBV DNA 
.are: (1) the presence oftandemly reiterated terminal direct repeats (TR) ofO. 5 Kbp 
longi8 and (2) oftandemly reiterated internal direct repeats (Rn) of 3 Kbp long^^ 
These tandem repeats divide the genome into short and long mainly unique 
sequence domains. These major DNA repeats are important landmarks on the EBV 
. 1 L 1 20-29 
genomic map. The general structure of the EBV genome is shown as below . 
TR-Ul-IRl-U2-m2-U3-m3-U4-ni4-U5-TR 
Fig. 1. Structure ofEBV genome consisting ofrepeats regions and unique regions. i 
TR represents terminal repeat sequence, Un are unique regions of the 
genome and K n are the tandem intemIl repeat sequences. Inside the infected cell, 
the virus DNA forms a circular episome with a characteristic number ofTR repeats 
as shown in Figure 2. 
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Fig.2 Genomic organization ofintranuclear episomaI form o f t h e EBV genome 
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l ^ h o c y t e cen lines ^ontaneously become p a s s i v e fbr virus r^lication ^.^^^^ 
characteristic cytopathic changes associated with herpes virus replication^. The 
transition from latent infection to lytic infection 咖 be induced by exposure to 
drugs that inhibit host macromolecular synthesis, superinfection with EBV, 
i — i t i o n of DNA methylation, cross-linking of surface — o g l o b u l i n and 
p,orbol ester stimulation ofprotein^kinase- The expression ofBZLF 1 gene is a 
key immediate e a r l y ^ c U v a t o r ofEBV lytic infection^ Lytic EBV infection 
in B lymphocytes in culture requires two to three days from maximum late lytic 
infection gene expression. 
1. 5 EBV Latent and Lytic Cycle Proteins 
Sequential changes occur in cells infected by EBV"] ^hese changes 
include the expression ofEBV immediate-early gene expression, cell enlargement, 
cell adhesion, RNA synthesis and B cell activation antigen expression leading to 
immunoglobulin secretion, DNA synthesis and cell divisW^^^. In latent infection， 
at least 11 EBV gene products are expressed. These are EBER1 and EBER2, 
EBNAs 1, 2，3A, 3B, 3C and LP. In addition, LMP1, 2A and 2B are expressed. The 
EBERs represent a small group of small nonpolyadenylated RNAs and are the most 
r 
abundant EBV RNAs in latently infected cells. They occur at about 10^  copies per 
49 50 
latently infected cel^49. Most of the EBERs are localized in the cell nucleus，. 
The functions ofthese EBERs proteins are still unknown. 
EBNA1 is another protein expressed in latently infected cells. It has a 
glycine alanine repeat domain. Most of EBNA1 except for the glycine alaline 
repeat domain is required for the episomal DNA replication. The carboxy-terminus 
appears to be necessary for episome persistence'^ Genetic studies analysis proves 
‘ 6 
供||iMflia^ritf • "t~*‘-"- *" -•*"*"—'~"™''**** —_ 
thatEBNA2 is essential forprimaryBlymphocyte growthtransformation^^^ EBV 
1 and EBV 2 differ most extensively in EBNA2 amino acids sequence^- . Studies 
have also shown that most or all of EBNA2's role in primary B lymphocyte 
growth-transformation is through — t i v a t i o n of cell or viral gene expression^. 
EBNA3A and 3C are essential for virus-mediated lymphocyte growth-
transformation, whereas EBNA3B^is nonessential for any aspect of lymphocyte 
infection. Much has to be leamed on the functions of EBNA 3A, 3B and 3C 切 v ^ 
LMP1 induces a wide variety of cell adhesion molecules on the cell 
surface. It also induces cell clumping and i n � a s e s villous projections. These 
adhesion molecules facilitate cell growth, since proliferating B lymphocytes secrete 
autocrine growth factors that may crossfeed each other. Thus, proliferation is 
heavily dependent on the effective cell concentration. The increased production of 
two of the adhesion molecule LFA-1 and LFA-3 lead to increased conjugate 
formation with T cells^ which result in the in v:vo elimination ofEBV-transformed 
B lymphocytes. This is important to host survival and perpetuation of latent and 
lytic Virus infection. LMP1 has also been shown to induce epithelial hyperplasia 
and alter keratin gene expressio^. The protein is able to transform rodent 
• 
fibmblasts6i,62 ^ d has activating effects in BL cells^^'^l LMP2 is known to 
downregulate the mobilization of calcium, indicating that LMP2 can modulate 
• 64 
transmembrane signal transduction . 
To summarize the expression and function ofproteins in latent infection, 
EBNA 1 binds to ori p and enables the EBV episome to replicate during the S-
phase. EBNA2 specifically ^ns-activates CD23, CD21 and ‘cfgr” as well as the 
LMP promoters. EBNA3C upregulates CD21 mRNA and protein synthesis but has 
7 
爭 
fraw5-activators of early EBV lytic gene expression. When these two mRNAs were 
translated into proteins, they trans- activate the expression of a cytoplasmic early 
protein from a second DNA fragment containing HRF1^^ Another immediate-early 
^rawj-activator may be encoded from the BILF4 ORF^^ However, the activity of 
this trans- activator is restricted to one or a few early promoters. 
Early lytic genes are defined as genes which consistently undergo 
•j 
synthesis in the absence ofDNA synthesis. Two of the early lytic gene products are 
‘SMLF1 and MRFl^ '^^ ®. SMLF1 is a promiscuous trans-actiYator of gene 
expression. HRF1 encodes another abundant EBV early protein. This protein is a 
18 kDa protein that consists of a predicted hydrophobic signal peptide, a 135 amino 
acid hydrophilic domain that contains two potential N-linked glycosylation sites, a 
hydrophobic potential transmembrane domain, and a short carboxy-terminal 
cytoplasmic domain^\ 
Other early proteins of EBV were identified by homology to the early 
genes of other herpesviruses. These classes of proteins are linked to DNA 
replication. These include DNA polymerase, major DNA binding protein, 
• * . 
ribonucleotide reductase, thymidine kinase and alkaline exonuclease. 
The next stage of EBV replication is viral DNA replication. As DNA 
replication starts, there is an increase in the episomal copy number suggesting that 
\ 
72 
these circular episome is a precursor to DNA replication . The origin of DNA 
replication has not yet been mapped as a sequence. However, there were two 
segments of DNA in the EBV genome which were thought to function as the 
7-^  
origins of lytic infection and viral DNA replication . 
• .. •',* - ..: ‘ . •. 
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After DNA replication, EBV late genes are expressed. These late genes 
which are either partially known or can be predicted from other herpesviruses 
coded mainly for the structural viral proteins or proteins that modify the infected 
cells so as to permit virus development or egress^^ The most studied of the late 
genes proteins are glycoproteins since they are important for humoral immunity. 
The most studied non-glycosylate protein is the major nucleoprotein capsid. It is 
coded for by the cLF 1 gene. cLFl is homologous to the major HSV capsid protein 
‘gene75. Another gene NRF1 probably encodes the major viron external protein^. 
Since the NRF1 sequence has no major hydrophobic domains, it is more likely to 
encode a tegument protein than to encode for an integral membrane protein. A late 
RNA from ORF XRF1 has homology to the varicella-zoster virus basic virion 
protein gene and is tentatively designated as an EBV basic core protein gene^^. 
The known structural glycoprotein genes are LLF1 (gp350/220), ALF4 
(gpllO), XLF2 (gp85) and ILF2 ^ '^^ ^ Both gp350/220 and gp85 are part of the 
membrane antigen complex. Glycoprotein gp350/220 is the dominant external virus 
glycoprotein which mediates virus binding ta the B lymphocyte receptor CD21. * . 
Glycoprotein gp85 is a relatively minor virus component which appears to be 
84 
important for the fusion between vims and cell membranes . Glycoprotein 
gp350/220 is the most abundant viral protein in the lytically infected cell plasma 
\ 
membrane and in the virus envelope. Most of the neutralizing antibody to EBV is 
85 . 
directed against gp350/220 and it is an essential component of any prospective 
EBV vaccine. 
, Table 1 summarize the different proteins expressed during the lytic 
� replication of EBV, immediate early proteins expressed during lytic infection of 
10 
EBV are mainly rra/z^-activators for the transcription of early protein gene. 
Secondly, most of the early proteins are functional proteins which participate in 
EBV viral DNA replication. Most ofthe late proteins are structural proteins for the 
assembly of the EB virus and assist in the egress of the virus from the infected 
cells. 
Table 1 Summary ofproteins expressed in EBV infection: 
4 
EBV Infection Proteins expressed 
Latent i n f e c t i o n “ EBNA1; EBNA2; EBNA “ " 
3A,3B,3C;LMPl;LMP2;EBERs(RNAs) 
Lytic infection ZEBRA;BRLFl(transactivator);BMRFl(EA-D);BHRF-~ 
l(EA-R);DNA polymerase;major DNA binding 
protein;ribonucleotide reductase;thymidine kinase; 
aDcaline exonuclease; gp350/220(MA); gpl 10; 
. gp85(MA); BcLFl(VCA); BNRFl(VCA; tegument 
protein). 
\ 
1. 6 CLINICAL DISEASES ASSOCIATED WITH EBV INFECTION 
EBV is an ubiquitous virus which infects abnost everybody either during 
childhood or in adolescence. Lifection in childhood usually occurs in 
z* 
underdeveloped countries^. Lifection in adolescence usually occurs in well-
..-^ c.� 
.i -i^X^-s < ‘ - • 
11 
developed countries and the infection may be due to kissing resulting in exchange 
of saliva 86，87. Mection in the adolescence may result in infectious mononucleosis 
88.89,92. However, infection in childhood is usually symptomless^. The Epstein-Barr 
virus results in several diseases. Childhood infection may result in acute childhood 
infection in symptomatic cases such as upper respiratory tract infection, 
hepatosplenomegaly and hepatitis'^ Infection in the adolescence results in 
infectious mononucleosis ' ' ' ' ' ' ' ' which usually has a raised titer of heterophile 
• antibody93. ^^^ gBV is also implicated in causing many lymphoproliferative 
diseases such as the Ducan syndrome which is a X-linked lymphoproliferative 
disease and is susceptible to lymphoproliferation after EBV infection. This is 
usually fatal in the male ^^ . 
Besides causing the above diseases, EBV is implicated as one of the 
causes ofdifferent cancers. In Afnca, it has caused widespread Burkitt's lymphoma 
(BL) when this virus was first discovered ^^ "^ 1 In this cancer of the lymph node, 
malaria is also a cofactor in Burkitt's lymphoma 今今’⑴。.Li South East Asia the 
incidence of nasopharyngeal carcinoma Q^C) is high, lta areas like the sourthem 
part ofChina, Malaysia, Singapore and Lidonesia there are high incidences ofNPC 
101-105 ’i06 It also occurs among the Eskimos in Alaska ^°^ The male to female ratio 
is 2:1 and the peak ofthe cancer occurs around 35-40 years ofage which then drops 
to a lower level as one gets older. It^ rate of infection is about 15-30 cases per 
10,000 per year i。；. Diet is a cofactor ofNPC i04，io7-iio，iiui2 Genetic makeup is 
, ^ 1 . . xror^ 103,104,110,113 




Hodgkin's lymphoma is a worldwide cancer with EBV as a cofactor 
. 1 1 9 
ns. However, the exact mechanism ofthe cause ofthe disease is still uncertain • 
1 120 
EBV is also invloved in gastric lymphoma . 
1.7. ASSOOATION OF EBV AND NPC 
• There are many evidences of association of NPC with EBV. First of all, 
喊 level of anti-BBV IgA is found « patients ofNPC ⑵ ’ 細 彳 Secondly in 
the tumour cells . o m NPC, EBV-spedfic - g e n s ^ d BBV D N A are always 
.detected in NPC cells -丨〕！ Thirdly, among the EBV antigens detected, two of 
these, namely EBNA and LMP 2A and 2B have been proven to be able to 
transform cells in culture into cancer cells ⑴’丨〕* These two antigens are expressed 
, i n NPC cel lPi35 ^ a _ o n , there is production of EBV viral particles and 
persistence ofviral DNA in NPC cells ^''. 
1. 8. EBV SEROLOGICAL MARKERS IN THE DIAGNOSIS OF NPC 
There are a number of EBV serological markers which are useful for 
screening populations at risks of developing NPC. These included the viral capsid 
anfigen (VCA)^^ which is the structural protein of the EBV nucleocapsid and can 
only be detected during the lytic cycle of EB virus, and the early antigen 
complexi24. j^ addition，viral specific membrane antigen present on the cell surface 
137 
ofthe infected cells are also important serological markers for NPC diagnosis • 
The Epstein-Barr Nuclear ai^ tigen (EBNA) can be detected in 100% of 
NPC cells. Antibodies against virus-specific these proteins had been indicated as 
markers for the diagnosis ofNPCi38. EBV-specific polymerasei39, ribonucleotide 
, reductasei, thymidine kinase^ and EBV-specific DNase^^^ are enzymes which 
—: occur early in the development of NPC. All these antigens serve as useful 
13 
serological markers for NPC and they are being investigated for the — diagnosis 
ofNPC 酬 5 . 
To determine the sensitivity and specificity o f u s i n g EBV-speciflc DNase 
as a marker for screening high risk groups of people at risk for NPC in a pop 
ulation，a surveyi^ 鄉 carried out in Taiwan. Sera from individuals were taken 
from four different groups ofpeople. The first group consist ofpatients with NPC, 
the second group ofpeople were from patients with other cancers, the third group 
. ‘of people were normal controls from government clinic employees and the last 
group of people were from individuals of different dialects and ethnics group. 
These sera were collected randomly. The sera from these groups of people were 
tested for anti-EBV DNase activities with neutralization test with greater of equal 
to 2 units of anti-EBV DNase activity as having a positive anti-EBV DNase result. 
Data from this study indicated that the anti-EBV DNase between patients with NPC 
and other groups being tested showed significant difference (P<0.001). This survey 
revealed that EBV-specific DNase is a good marker for field surveys with the aim 
� ofdetecting high risk people for NPC. The sensitivity of using DNase as a marker 
for the survey was reported to be 90.3% and the specificity was 94.7%. In another 
studyi47, it was shown that in NPC patients, the positive rate of anti- EBV DNase 
was significantly higher than other cancers such as cervical and lung cancers etc. 
The results of the evaluation in this L d y showed that anti-EBV DNase test had 
87% sensitivity and 95% specificity. Another study^'' showed that anti-EBV 
DNase test correlates to different stages ofNPC. In addition, anti-EBV DNase had 





1. 9 Sources ofEBV-specific DNase 
There are a number of sources to obtain EBV -specific DNase. First of all, 
it can be obtained from B95-8 cell line which is a marmoset cell line infected with 
EBV associated with infectious mononucleosis. The yield of the EBV -specific 
DNase can be increased by n-butyrate induction. The second" source of EBV-
specific DNase can be obtained from latently infected lymphoblastoid line 
superinfected with EBV infected cell line, such as the Raji cell line. 152,153. The 
. . third source of DNase could be obtained by chemical induction of the EBV latent 
infected cell lines such as D981Hr-1 induced by 5-iodo-2'deoxyuridine (IUDR)153 
and P3HR-I cells or Raji cells induced by phorboester and sodium butyrate l54-
158,148. Although there are many different sources ofEBV-specific DNase, they all 
suffer from a disadvantage. Very large amount of cell culture (up to 10 litres) is 
required to obtain minute quantity ofEBV-specific-DNase 159. 
1. 10 Characteristics of Epstein-Barr virus alkaline DNase 
The Epstein-Barr virus DNase has been widely studied and has been 
considered as a good diagnostic marker for screening populations for high risk 
groups for developing NPC. It has also been shown to be a good prognostic marker 
for the treatment ofNPC. It is therefore important to study the characteristics of this 
EBV DNase in various virus-producing lymphoblastoid cells. In one study carried 
\ 
out by Baylis160 et al. , recombinant EBV DNase expressed in E. coli161 had been 
used in the production of an antiserum in mice. The antiserum was raised in mice 
inoculated with the EBV DNase with Freund's incomplete adjuvant. The antiserum 
was shown to react with the recombinant protein in both Western blot and enzyme 
neutralization tests. This serum was then used to examine lymphoblastoid cells 
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expressing EBV antigens. The cell lines were B95-8, Raji, P3HR-l, Namalwa, DG-
75 and Ball-l cells 162. The latter two were both EBV. negative human B cells. The 
results showed that this antiserum was able to neutralize DNase activity in B95-8, 
Raji and P3HR-l cells induced with TPA and BUdR but not in the EBV-negative 
cell line Ball-l even after chemical treatmentl60. This proves the specificity of the 
recombinant DNase purified from E. co/i160• 
To identify the polypeptide associated with the DNase in EBV harboring 
. ·lymphoblastoid cells producing EBV antigens, cell extracts from B95-8, Raji cells 
and P3HR-l cells were prepared and analyzed by Western blot analysis. The result 
showed that no immunological reaction was detected in non-chemically induced 
cells and the EBV negative celllines16o• Moreover, results also showed that the Mr 
of the detected polypeptide was larger than those obtained from the cloned BGLF5 
gene expression160. Therefore it was concluded that some post-translational 
modification of the EBV DNase protein may occur in the induced EBV cell line 
and these modifications may be lacking in E. coli which was used to clone and 
. expressed the.EBV-specific DNase protein160. 
Besides these groups of investigators, another group of investigators have 
demonstrated that NPC sera only neutralize EBV DNase produced by TP A-induced 
HR-I cells and Raji cells superinfected with HR-I virus165 , NPC sera did not 
\ 
neutralize TPA-induced B95-8 cells or 'Raji cells superinfected with B95-8 virus165. 
There were also differences in electrophoretic mobilities of EBV DNase in Raji 
cells superinfected with HR-I virus and Raji cells superinfected with B95-8 cells. 
This suggested that B95-8 induced DNase may be anti genically different from the 
DNase induced by the HR-I virus. Therefore, it is possible that there may be 
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different variants among EBVs and that they might produce DNases of different 






l . l l A i m ofthe Project 
The main aim ofthe project is to clone the EBV-specific DNase gene from B95-8 
and Raji cell lines. The second aim is to compare the nucleotide sequence 
variability ofthe fimctional domain ofthe DNase gene in B95-8 and Raji cells. The 







CHAPTER2. M — n l ^ & Methods 
2.1. Molecular cloning 
2.1. 1. Cell culture: 
B95-8 and Raji was used as the cell line for the production ofviral mRNA. 
n-butyrate was used as an inducer for lytic infection of EBV and was used at 
3mMi66. The culture was then incubated for a further 96 hrsi66. ^he culture medium 
,u sed was RPMI 1640 medium (GBCO BRL) supplemented with 200mM 
glutamine (SIGMA), 2Qo/o fetal calf serum. Hepes (GffiCO BRL) and sodium 
bicarbonate (BDH) were used as the buffering system. The cells were incubated at 
, 2 > r C in a 5% carbon dioxide environment. The cap of the flask were kept loose and 
the flasks were incubated upright. The cells were harvested at 96 hrs after 
incubation. Sixteen 25 mls of confluent cells would provide enough cells for 
mRNA extraction. 
2. 1. 2 mRNA purification: 
For the disruption ot the- B95-8 cells,;cUltures were transferred to 50 ml 
• V 
conical tubes and centrifuged at 2000 rpm for lOmins. The supernatant was 
discarded and the cell pellets from the sixteen flasks were pooled in an eppendorff 
tube. The eppendorff tube containing the pooled cells was then briefly and the 
‘ \ 
remaining supernatant was poured off, 0.4 ml of extraction buffer (Pharmacia) 
containing guanidinium thiocynate and N-lauroyl sarcosine was added to resuspend 
the cellsi68,i69，i70 Elution buffer (Pharmacia) containing lOmM Tris-HCL(pH 7.5) 
, and lmM EDTA was then added to dilute off the disrupted cells. The cell lysate 
was then vortexed after the addition ofthe elution buffer (Pharmacia). To obtain a 
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clear cell lysate, the eppendorff tube was centrifuged at 65000rpm in a Micro 
Centaur™ centrifuge (MSE) for 1 niin. Oligo(dT) ... Cellulose167 (Phannacia) was 
used to trap the mRNA from the disrupted cells. The oligo(dT)-Cellulose was 
suspended in a storage buffer. One ml aliquot was used. The oligo(dT) slurry 'was 
gently swirled to form a uniform suspension. Each ml of oligo( dT) was placed in an 
eppendorff tube and centrifuged. The supematant was then removed and the tube 
was capped. 
One millilitre of the cleared cell lysate was placed in the centrifuged 
Oligo( d-T) cellulose (Pharmacia). The tubes were then inverted manually and 
mixed for 3 mins. The tubes were then spun at 65000rpm in the Micro Centaur™ 
centrifuge (MSE) for IO sec. The resultant supematant was pipetted off and 
discarded. 
The pellet was resuspended and washed with I ml of high-salt buffer 
(pharmacia) consisting of IOmM Tris-HCl (PH 7.5), ImM EDTA and 0.5M NaCl. 
It was then centrifuged for 10 sec. at 65000 rpm for IO sec. The supematant was 
discarded. This ,was repeated for four mqr~ tim~s. One millititre of low-salt buffer 
(Pharmacia) containing 10mM Tris-HCI (PH 7.5), 10mM EDTA and 0.5M NaCI 
was then added. The pellet was resuspended in the lo~-salt buffer and centrifuged. 
The supematant was pipetted off and discarded. This was repeated one more time. 
, 
The resin with the bound mRNA was then resuspended in 0.3 ml of low-
salt buffer and the slurry was transferred to a Microspin column (promega) placed 
in a microcentrifuge tube. This was spun for 5 seconds. The effluent was discarded 
and 0.5 m! of low-salt buffer was added to the column carefully. This was 
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centrifUged for 5 sec afterwhich the effluent was discarded. This was repeated two 
more times. 
The microspin colunm was placed in a clean sterile centrifuge tube and 0.2 
ml ofelution buffer containing lOmM Tris-HCl (pH 7.5) with lxnM EDTA wanned 
at 650C was added to the column. This was centrifuged for 5 sec after which the 
column was removed and the resultant mRNA eluate was placed on ice. 
The concentration of the mRNA was determined at A ,o by the capillary 
method in which a very small portion of the mRNA was sucked up by capillary 
action into a small bore capillary tube and this was placed in a special cuvette 
which could accommodate the capillary tube. Elution buffer was used as the blank. 
2. 1 • 3 First strand cDNA synthesis^i 
The RNA sample from the last step was placed in a microcentrifuge tube 
and and dried under vacuum. Then RNase-free water treated with diethyl-
pyrocarbonate (DEPC) was added to bring the volume to 20 ul. The RNA solution 
was heated to 65�C for 10 mins and then chilled on ice. The reaction mix contains 
11 ul o fBuU. First-strand Reaction mix (Promega), 1 ul of primer amounting to 0,2 
.. •• 
• ug, 1 ul ofDDT solution, 20 ul ofRNA (13. 6 ug). The total volume was 33 ul. 
The BuUc First-strand reaction mix (Promega) contain Cloned FPLC purified 
Murine Reverse Transcriptase, RNaseADNase free BSA, dATP, dCTP，dTTP，dGTP 
in aqueous buffer. The DTT solution contain 200mM DTT in aqueous solution. The 
primer used for reverse transcription is p d _ primer and is a random 
hexadeoxynucleotides used at 0. 2 ug/ul in aqueous solution. The above mixture 
, was mixed by pipetting and incubated at 37�C for one hour. 
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2. 1. 4 Polymerase chain reaction (PCR) of cDNA 
The solution ofPCR contained IX PCR buffer, 6 ul of IOmM dNTP, 6 ul 
of 10 mM MgCI2, primer A and primer B at 10 ul of IumoVml each. 7.5U ofTaq 
polymerase was added with 5 ul of 1 st strand DNA, double distilled water was 
added to make up the volume to 100 ul. The PCR reaction was carried out at 95 QC 
for Imin , 55 Q C for 2 mins , and 72 QC for 2 mins. This was repeated 30 times. 
Primer A was situated at the 5' end and primer B at the 3' end of the EBV -specific 
DNase cDNA sequence. The gel was run at IOOV for 1.5 hr. 
Primer A: 5'-ATG GCC GAC GTG GAT GAG CTC-3' 
Primer B 5'-TTA TTC CCC CGT CCA CGT CGC CTA-3 
Then, 1 % agarose gel with EtBr was used for gel electrophoresis of the 
PCR product. Phi X 174 HaeIII was used as a molecular weight marker. 
2. 1. 5 Purification of PCR Product after gel electrophoresis 
An empty eppendorff tube was weighed before use and the weight was 
noted. A clean razor blade was used to cut the agaorse band containing the PCR 
product.. In order to reduce the )veight of the agarose band , the agarose was cut as 
. -
close to the band as possible. The agarose slice was chopped into small pieces and 
put in the eppendorff tube. The agarose slice togethe~ with the eppendorff tube was 
reweighed and the weight of the agarose slide was calculated. Two hundred and 
\ 
fifty microlititres of gel solubilizer (phannacia) containing sodium iodide in Tris-
HCI buffer (PfJ 7.5) was added and it was vortexed vigorously and incubated for 5-
lOmins in a60 Q C water bath until the ag~orse slice had dissolved. The sodium 
iodide would dissolve the agarose slice and at the same time provided sufficient 
quantity for binding of DNA to the glass matrix later on. The container bearing the 
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glass matrix was shaken to form a uniform suspension. Ten microlitres ofthe glass 
matrix (Phannacia) was added to the dissolved slice and vortexed gently. It was 
incubated for 5 mins with periodic shaking at every minute. It was then centrifuged 
for 1 min at 65000rpm. The supernatant was discarded. The glass matrix 
(Pharmacia) with the bound DNA was then washed three times with 40 ul ofwash 
buffer containing buffered ethanol (Pharmacia). After centrifugation at 65000 rpm, 
the glass matrix (Pharmacia) with the bound DNA was inverted to dry off all the 
.‘wash buffer. Elution buffer (Phannacia) containing lOmM Tris-HCl(pH 8.0), lmM 
EDTA was added at 10 ul and incubated for 5 mins. at room temperature with 
periodic resuspension every 1 min. interval. It was then centrifuged at high speed 
. a n d the supernatant containing the DNA was then saved in a clean sterile 
eppendorfftube. This step was repeated once to get a better yield ofDNA. 
2. 1. 6 Ligation ofPCR amplified DNase gene into pUC18 Sma I/BAP vector 
Twenty microlitres ofPCR product from above was put in an eppendorff 
tube. One microlitre ofKlenow fragment of R coli DNA polymerase (5-lOU 
p,omega ) was added. Two and a half microlitre of One-Phor-All buffer 
(Pharmacia) was added subsequently. Two microlitre of dNTP (lmM) was added 
and the mixture was incubated at room temperature for 15 mins. To add a 
phosphate group at the 5’ end ofthe blunted PCR DNase gene phosphorylation was 
\ 
carried out in the same tube. 
For 5，end phosphorylation, 1 ul of T4 polynucleotide kinase ( Promega) 
was added followed by 5 ul of ATP at 0. lM and 3.5 ul of 10X PNK buffer 
, (Pharmacia). The tube was incubated in a water bath at 37® C for 30 mins. 
“ " - ' • . - -• .’ -.-•• • • • -.. • 




To purify the phosphorylated DNA, 20 ul of phenoVchloroform (BDH) 
was then added followed by vortexing and separation of the aqueous phase from the 
organic phase by centifugation for 1 min at 65000rpm. The upper aqueous phase 
was collected. This aqueous phase containing the EBV DNase gene and was fUrther 
purified by binding to a Microspin™ column (Pharmacia) using a Sephacryl S-
200™ resin (Pharmacia). The bottle of Sephacryl S-200 was inverted several times 
to resuspend the resin. The Microspin column was placed on an eppendorff tube. 
. ‘F ive hundred microlitres ofthe resuspended resin was transferred to the column. It 
was then spun to remove the buffer from the column. The effluent was discarded. 
The microspin column together with the resin was placed in a new microcentrifuge 
tube. The extracted PCR product was slowly applied to the center of the resin bed. 
It was then centrifuged at 65000rpm for 30 sec. The effluent was saved for ligation 
and the column was discarded. 
Fourteen microlitres of the insert EBV DNase gene (50 ng) from the 
Microspin column effluent was combined with 2 ul of T4 DNA ligase (Takara), 4. 
. '. • •  “ • • 
2 ul of 5x'ligase buffer (BRL) and 1 ul of the pUC18 (50 ng) Sma^BAP. The 
mixture was incubated in a 16°C waterbath overnight. 
. 
2. 1. 7 Transformation by Electroporation 
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2.1.7. 1 Cell preparation 
The stock E. coli JM105 was streaked onto a LB plate. After overnight 
incubation, a single colony from the plate was picked and grown into 5 ml of LB 
medium at 3 7 � C on a platform shaker. After ovemight incubation, 2.5 ml of the c 一 
, ulture was put into a 500 ml LB medium in a sterile 2L flask. It was grown at 37� 
C on a rotary platform at 200rpm until the 0 . D.550nm reached 0. 5 to 0. 8，i. e. log 
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phase. The cells were chilled in an ice-water bath for 10-15mins and then 
transferred to a lL prechilled centrifuge bottle. The cells were centrifuged at 4000 
rpm for 20 min and the supematant was discarded. The cells were resuspended in 5 
ml ofice-cold water. After resuspension, 500 ml ofice-cold sterile water was added 
and mixed well. The suspension was centrifuged at 4000 rpm for 20 mins. and the 
supematant was poured off immediately. Another 500 ml of ice-cold water was 
added and the suspension was mixed well. It was then centrifuged at 4000 rpm for 
• 20 mins. The supematant was poured off and the cells were resuspended in the 
remaining liquid. Forty millitires ofice-cold • glycerol was added to the cells 
and put in a pre-chilled tube. It was then centrifuged at 4000 rpm for 10 mins. The 
, s u p e m a t a n t was poured offand the volume ofthe cell pellet was estimated. Finally, 
an equal volume of ice-cold 10% glycerol was added and the cells were 
resuspended. The cells were aliquoted in 100 ul portion in pre-chilled eppendorff 
tubes and stored at -70�C 
2. 1 • 7. 2 Electroporation procedure 
B T X ™ disposable cuvettes were used as' a reaction chamber. The cuvette was 
chilled on ice. One LB plate with ampicillin was put at 37C for each 
electroporation. The sample volume was 50 ul of cells and the transfectant volume 
was 0.5ug of plasmid. They were mixed by shaking gently to settle the cells to the 
\ 
bottom of the cuvette. The cuvette was then chilled on ice for 1 min prior to 
electroporation. The cuvette was put into the sample chamber. The pulse was 
applied by pushing the button. The cuvette was immediately removed and 960 ul of 
z SOC medium was added. This step is critical and should not be delayed. The SOC -
二 一 medium with the cells were gently pipetted up and down to mix. The mixture was 
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2.2 Extraction ofPlasmid DNA 
174 
2. 2. 1 Boiling Preparation 
Several white colonies (usually 20) were picked from the LB plate 
supplemented with ampicillin (Sigma)，X-gal (Promega) and H>TG (Sigma) with a 
sterile toothpick and put in a universal bottle with LB and 60 ug/ml ampicillin 
(Sigma). The cap ofthe bottle was loosened and taped. The bottle were then shaken 
• in a rotating platform at 300 rpm ovemight (usually 16-20 hrs ) at 3 7 � C . 1. 5 ml of 
the culture was put in an eppendorfftube. It was then centrifuged at 65000 ipm at 
40 c for 30 sec. The supernatant was discarded. The eppendorff tube was inverted 
on a paper towel to drain the remaining culture medium so that the bacterial pellet 
was as dry as possible. 
The bacterial pellet was resuspended in 350 ul of STET buffer containing 
0. 1 M NaCl, 10 mM Tris.Cl (pH 8.0), 1 mM EDTA(pH 8.0) and 5% Triton X-100. 
The pellet was resuspended in STET by vortexing two eppendorff tubes sim 
ultaneously with their bases touching each other in the vortexer. After that, the 
tubes were placed in a boiling water bath for about 40 seconds. 
The bacterial lysate was centrifuged for lOmins at 65000rpm in the Micro 
Centaur™ centrifuge to spin down the chromosomal DNA and any remaining 
\ 
bacterial cells, leaving the plasmid in the supernatant. The bacterial chromosome 
was removed from the tube with a sterile toothpick. Subsequently, 35 ul of 3M 
sodium acetate and 420 ul of isopropanol were added and vortexed. This was stored 
, for 5 mins at room temperature to precipitate the plasmid DNA, The tubes were 
’ ^ ^ ^ , . . then centrifuged at 4^C for 5 mins to recover the DNA pellet. After centrifugation, 
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the plasmid DNA in the screw-capped tube was pipetted in a 2 ml screw-capped 
and stored at -20C before further processing. 
2. 4 Small scale purification ofplasmid 口石 
This was done to obtain a more pure DNA preparation before DNA 
sequencing since the more pure the DNA, the better the bands on the sequencing 
gel would emerge. Fifty microlitres from the large-scale purification was used for 
this procedure. One ml of Wizard DNA Clean-up Resin (Pharmacia) was added to 
, t h e plasmid DNA in a 1.5 ml microcentrifuge tube. The microcentrifuge tube was 
inverted several times to get a uniform suspension of resin. A 5 ml syringe was 
attached to the luer-lock of a minicolumn ( Pharmacia) which contain a small filter 
near the tip ofthe minicolumn to trap the resin ( Pharmacia ). The syringe with the 
attached minicolumn was fitted in a vacuum manifold via the tip of the 
minicolumn™. The resin suspension from the 1.5 ml microcentrifuge tube was 
pipetted into the syringe barrel and a vacuum was applied to draw out the liquid 
portion of the resin mixture leaving the dried resin on the minifilter on the , 
minicolumn. The resin on the filter was washed with 2 mls of 80% isopropanol. 1 
The minicolumn was detached from the vacuum manifold and the syringe barrel • 
and placed on top of a 1.5 ml microcentrifuge tube. It was then spun at 65000 rpm 
to get rid of any residual ethanol which might interfere with subsequent reaction. 
The eluate was discarded and the miniiolunm was dried at 37° C for 15 mins to let 
the residual isopropanol to evaporate. After drying, the minicolumn was put on top 
of a microcentrifuge tube. 50 ul of pre-warmed (65-70C) sterile distilled water was 
added to the minicolumn to elute the bound DNA. The pre-warmed water was 
. - — - , - — — 
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resin. It was then centrifuged for 65000 rpm. 10 ul ofthe eluate was diluted 100X 
with sterile distilled water to 1ml and A:6o was measured in a quartz cuvette to 
determine the purity and the yield ofthe DNA. The eluate was saved at - 2 0 � C for 
DNA sequencing. 
2. 5 DNA Sequencing 
The di-deoxy DNA sequencing method can be conveniently divided into 
four parts: 
.2. 5. 1 Annealing ofPrimer to template DNA � 
The concentration of the template from the two purification step 
mentioned above i.e. the pUC18/EBV DNase, was adjusted to 1.8 ug/ul with sterile 
distilled water after measurement with a spectrophotometer at 0 . D. 260- One 
hundred microlitre of the template was used. This amounts to 180 ug of template 
DNA. To separate the double stranded template DNA into single strand, 24 ul of 
2M NaOH was used, and the mixture was incubated at 37C for 30 mins. After 
denaturation, the solution was neutralized by 24 ul of 3M sodium acetate at pH 5.2. 
The denatured DNA was precipitated with 370 ul of 100% ethanol at -70 °C for 15 
mins and collected by centrifugation. The DNA pellet was then washed with 370 ul 
70% ethanol and centrifuged for 2 mins. at 4° C. The DNA pellet was resuspended 
in 6 ul ofsterile distilled water. Two microlitres (8 pmol) ofthe forward or reverse 
primer(8 pmol) was added with 2 ul o)f annealing^^ buffer (Pharmacia) containing 
lM Tris-HCl (pH7.6), 100 mM MgCl2 and 160 mM DTT The mixture was 
incubated for 30 mins at 3 7 � C . The sequencing reaction were separately done in 





insert (forward sequencing) and one from the 3' end of the EBV-specific DNase 
insert (reverse sequencing). The forward and reverse primers were as follows: 
Forward primer: 5 'AACAGCTATGACCATG3' (primer 1) 
Reverse primer: 3 'TGACCGGCAGCAAAA TG 5' (primer 2) 
They were both flanking the polycloning site of the pUC18 plasmid. 
Because there was a limit where a primer could extend from the 5' and the 3' ends, 
extra primers in the middle of the EBV -specific DNase insert were needed to start 
. 
. the sequencing in other locations beyond the limit of the forward and reverse 
extensions. These were done separately for each primer. 
The extra primers situated in the middle of the sequence were: 
Primers Nucleotide position 
Primer 3: 5'-GCCGTGGATTGATG-3' 381-394(forward) 
Primer 4: 5'-TCGGAGGGTGACTATCTGTT -3' 597 -578(reverse) 
Primer 5: 5'-AACAGATAGTCACCCTCCGA-3' 578-597(forward) 
Primer 6: 5'-GCCAGCTCCCATCTCCACAA-3' 1000-881(reverse) 
(8 pmol of each primer in each annealing reaction) 
2. 5.2 Labelling reaction 
The choice of labelling nucleotide was a-35S dATP(> 100 Ci/mmol, 
Amersham). The mixtures of nucleotides for sequencing were divided into short 
\ 
sequencing mix (running electrophoresis for 2.5 hr) . and long sequencing mix 
(running electrophoresis for 8 hr). Two and a half micro litres of of A Mix-Short,C 
Mix-Short, G.mix-Short and T mix-Short, all from Pharmacia was pipetted into the 
corresponding wells of a specially designed microsample plate with a fixed set of 
dimples for each plate. These were the four short sequencing mixes. 
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Before commencing, 1.0 ul of T7 DNA polymerase( 8.5 units ) was 
diluted with 4.0 ul of Dilution Buffer™ and put on ice ready for use in the 
subsequent step. To a 0. 5ml microcentrifuge tube, the following was added: 
Annealed template/primer 10 ul 
Labelling Mix(for dATP) 3 ul 
Labelled a-^^ S- dATP 1 ul 
• ' Diluted T7 DNA polymerase 2ul 
Total volume 16ul 
The content was mixed by gently pipetting up and down and incubated at 
room temperature for 5 min. While this incubation was in progress, the four 
sequencing mixes in the dimple ofthe microsample plate were warmed at 3 7 � C for 
at least 1 min. by floating, with its lid on in a 37 °C waterbath. Labelling mix (for 
dATP) contains 1 • 375 uM each of dCTP, dGTP, dTTP and 333. 5 uM NaCl. 
2. 5. 3 Sequencing termination reaction 
After the labelling mix has been incubated for 5 mins. 4.5 ul of this 
reaction was transferred into each ofthe four pre-wamed sequencing mixes in the 
dimples of the microtitre plate using a fresh pipette tip for each transfer. Each 
sequencing mix contained one of the ddNTP and three of the deoxyribonucleotides. 
The component was mixed by gently pipetting up and down. The plate was 
incubated for 5 mins in a 37° C waterbath covered with a lid. 
, After incubation, 5 ul of stop solution was added to each well and mixed gently, 
the stop solution contained 0.3% each ofBormophenol Blue and Xylene Cyanol FF ‘ 
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which were dyes for estimating the electrophoresis distances, 10 mM EDTA ( pH 7. 
5) and 97.5% deionized formamide. Then the sample was heated at 1 0 0 � C on a wet 
block heater with boiling water for 2 mins. It was then immediately chilled on ice. 
2. 5. 4 Preparation of Sequencing Gel 
The LKB 2010 Macrophor electrophoresis unit was used for DNA 
sequencing. It consisted of an upper tank and a lower tank for holding 
‘electrophoresis buffer. There was an assembly in front of the two gel tanks for 
holding the gel in place with clips. The front glass plate for holding the gel 
contained a space for the flow ofwater preset at a particular temperature. This plate 
was connected to a multi-temp water bath which could preset the temperature of the 
water flowing through the front glass plate. The sequencing gel was hold between 
the front and the back glass plate. Therefore, there were two glass plates to be 
assembled. To assemble these two glass plates, the front glass plate was put on a 
horizontal carriage. The plate was rubbed two times with 70% ethanol with a lint-
free Kimwipe to remove oil and dust . The back glass plate was rubbed with 70% 
ethanol as the front plate and put aside for the meantime. Acrylase was sprayed on 
the back plate and rubbed dry. This step was repeated one more time. The acrylase 
made the gel to stick on the back plate after the gel was set. 
\ 
Then, two 0.35 mm spacers were put at the edge of the front glass plate which was 
now on the horizontal carriage and were hold in that position by three clips. The 
back glass plate was put on a slider of the gel pouring apparatus with the upper 
z- edge of the back plate just touching the lower edge of the front plate. 
( 
Gel solution was prepared as follows: 
f 
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100 ml 6% acrylamide gel solution containing 6g acrylamide in 100 ml 
TBE (Tris-boric acid ,EDTA) buffer, 0.31g N’N’-
methylenebisacrylamide and 60% urea. 
600 ul of 10% ammonium persulfate 
30 ul TEMED 
The gel was made as follows: Some gel solution was poured at the lower 
end of the front glass plate. The back plate was slided towards the top of the front 
I 、“ 
.plate. In doing so, more gel solution was added so that a thin film of gel solution 
was formed between the front and the back plate. After this has been done, the clips 
for the spacers were moved inwards to clip the front and the back plate together. 
Then, a 0.25 mm gel comb was inserted at the top of the gel with the flat edge of 
the comb facing towards the gel so as to make a flat surface on the top part of the 
gel. 
A steel band was put at 1/3 distance from the top part ofthe gel. The gel would be 
set in 3 hr . After the gel has set the top edge of the gel was washed with water to 
get rid of excess urea. The gel were then placed on the gel rack and clipped tightly 
against the gel rack. 1600 mls of gel buffer consisting ofTris borate buffer made of 
1.08 Tris base 5.50g boric acid 0.5M EDTA (jpB 8.0) at 4 mls amount and making 
up the volume to 1 L with distilled water. This amount was divided between the top 
and the bottom tank, the host was connected to the water bath which set at 50 °C. It 
was turned on to set the temperature ofthe gel at 50 °C. A shark-teethed comb was 
placed at the upper edge ofthe gel with the teeth just touching the top part of the 
gel. This would form a barrier between each well. There were a total of 12 wells. 
Two microlitres of the denatured sample was put into each well of the sequencing 
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gel. One pipette tip was used for all loadings after adequate washing in buffer after 
each loading. The gel was electrphoresed for 2.5 hrs at 60W at 50 ^C for ‘short run， 
and8hrsfornong run'. 
2.5.5 Autoradiography of sequencing gel 
After finishing each run, the gel buffer at the top of the tank was emptied 
by opening the tap at the top tank and allowing the buffer to flow out into a large 
conical flask. The same was done with the lower tank. The gel with the glass plate 
‘was removed from the gel apparatus and placed on a flat surface with the back plate 
on top ofthe front plate. A flat spatula was inserted between the two glass plate and 
was then slowly twisted to separate the two glass plate being careful ofnot tearing 
the gel. The gel would stick to the front plate when the back plate was lifted up. A 
Whatmann 3MM paper cut to the size ofthe gel was placed on top ofthe gel. The 
gel would adhere to the filter paper this was flipped over. A plastic wrap was placed 
on top of the gel. The wrap was stretched over the gel so that there would not be 
I 
any bubbles or creases. The gel was placed in a gel dryer ( Biorad ) with the 
Whatmann 3MM paper facing down on the porous surface of the gel dryer and the 
plastic wrap facing upwards. The gel was covered with a plastic cover. Then a 
vacuum was applied through the porous surface ofthe gel drying apparatus. The gel 
dryer was then covered and the gel was dried at 80 ^C for one hour. 
\ 
After the gel had been dried, the gel would had stuck to the Whatmann 
3MM paper as a thin film. Then the saran wrap was peeled off gently. Talcom 
powder was smeared onto the gel and an X-ray film(Agfa Curix Medical X-ray 
z fihn) was put on top of the gel in the dark. The gel with the X-ray fi to was sealed 
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ray fihn was developed and fixed after which it was left to dry by hanging the X-
ray fihn up with a clip on a string. The bands on the X-ray fihn was then read. 
2.6 Epitope Mapping 
2.6.1 Processing ofEBV-speicfic DNase Peptides 
The commercially prepared peptides came in 5 mg amounts and 1 ml of 
PBS pH 7.2 was added to each peptide. This resulted in a peptide concentration of 5 
mg/ml. Then, a ten fold dilution was made by mixing 900 ul PBS and 100 ul of the 
.peptide solution. The resulting peptide concentration was 500 ug/ml. A further ten 
fold dilution was made resulting in 50 ug/ml of peptide. This was equivalent to 2.5 
ugy'50 ul of peptide. These dilutions were stored at -70° C until use. For Enzyme-
linked immunosorbent assay �”，200 i^l of 50 ug/ml of peptide solution was added to 
800 i^l of 10 mM carbonate buffer at pH 9.6’ 100 ^1 of each of these were added to 
the corresponding wells. The plates were divided into six sections with one section 
per serum. For each section, there would be enough wells for three antigen-negative 
controls. For the negative controls, 100 ^1 ofcarbonate buffer were added. The plate 
was covered in a humid box at 4�C for 18 hrs. Afler overnight incubation, the plates 
were washed once with PBS/Tw with an automatic plate washer. The soak time . 
between each wash was 30 sec. Then 100 jiVwell of PBS/^SA were added per well 
and the plate was incubated for 2 hrs at room temperature. The plate was then washed 
three times in PBS/Tw with soak time�of 30sec. Fifty microlitres per well of serum 
diluted at 1:50 in PBS/^SA-Tw was added and allowed to react for 2 hr. at room 
temperature. The plate was washed 4 times in PBS/Tw as above. A peroxidase ^ 
. i 
conjugated anti-human IgA diluted at the recommended dilution was added at 50 ^1 ! 
z •»:. � iti 
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and the plate was incubated for one hour at room temperature in a hunud box. The 
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ray film was developed and fixed after which it was left to dry by hanging the X-
ray fihn up with a clip on a string. The bands on the X-ray fihn was then read. 
2.6 Epitope Mapping 
2.6.1 Processing of EBV-speicfic DNase Peptides 
The commercially prepared peptides came in 5 mg amounts and 1 ml of 
PBS pH 7.2 was added to each peptide. This resulted in a peptide concentration of 5 
mg/ml. Then, a ten fold dilution was made by mixing 900 ul PBS and 100 ul of the 
• peptide solution. The resulting peptide concentration was 500 ug/ml. A further ten 
fold dilution was made resulting in 50 ug/ml of peptide. This was equivalent to 2.5 
ug/50 ul of peptide. These dilutions were stored at -70° C until use. For Enzyme-
linked immunosorbent assay ”，，200 |il of 50 ug/ml ofpeptide solution was added to 
800 p,l of 10 mM carbonate buffer at pH 9.6，100 |il of each ofthese were added to 
the corresponding wells. The plates were divided into six sections with one section 
per serum. For each section, there would be enough wells for three antigen-negative 
controls. For the negative controls, 100 i^l of carbonate buffer were added. The plate 
was covered in a humid box at 4�C for 18 hrs. After overnight incubation, the plates 
were washed once with PBS/Tw with an automatic plate washer. The soak time 
between each wash was 30 sec. Then 100 ^Vwell of PBS/BSA were added per well 
and the plate was incubated for 2 hrs at room temperature. The plate was then washed 
three times in PBS/Tw with soak time of 30sec. Fifty microlitres per well of serum 
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temperature. The plate was washed 4 times in PBS/Tw as above. A peroxidase 'i' 
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conjugated anti-human IgA diluted at the recommended dilution was added at 50 \d ii 
^ SI 
. i and the plate was incubated for one hour at room temperature in a hunud box. The 
i 
• I 
4 . I 
39 ； 1 . .1 
. •” I ^ ^ ^ ^ ^ • H ^ ^ ^ ^ ^ ^ H ^ ^ ^ H H H ^ ^ H ^ H ^ ^ ^ ^ ^ ^ H i ^ ^ ^ ^ H B i ^ » _ 
plate was then washed five times in PBS/Tw as above. After this, 50 uVwell of the 
enzyme substrate o-phenylenediamine was added. Then, 0.4 mg/ml of 0.01% 
hydrogen peroxide in citrate phosphate buffer (pR 5.6) was added and incubated in a 
humid box for 37 °C. The reaction was then stopped by adding 50 uVwell of 4M s 








rTTAPTFJR :¾ Results 
3.1 Molecular Cloning 
3 .1 .1 Cell culture: 
Under the microscope, B95-8 cells were clumped and suspended in the 
medium. A small number of cells will stick to the surface of the flask but the 
majority of them remained suspended. Some of the cells were detached from the 
clumps and floated alone in the medium. The pH ofthe medium was quite constant 
. a t pH7. 4 when it was changed every two days. However, the medium will quickly 
turned alkaline in prolonged incubation of more than two days. Cell counts by 
haemocytometer results in about two million cells per ml of culture. This applied to 
culture supplemented in 20% fetal calf serum only. Those suspended in 10% fetal 
calf serum only yielded 50,000 cells per ml. Addition of trypan blue to such cell 
clumps reviewed that these cells were viable. Results showed that sixteen flasks, 
each with 25 ml ofcell culture, werejust enough for mRNA extraction. 
Cell contamination is not a problem with B95-8 cells. 
3.1. 2 mRNA Purification: 
After the addition of the extraction buffer, the cell lysate was quite 
viscous. Vortexing results in the complete lysis of cells. The cell lysate became 
clear after centrifugation. The absorbance value after purification at 260 nm was 
\ 
0.34. The absorbance value at 280 nm was 0.136. The following formula was used 
to calculate the concentration ofmRNA: 
, � 
‘z' 
• -^- .,- .•+-.. • • 
50 
[RNA] = A26oX40 ugAnl 
0. 34 X 40 ugAnl = 13.6 ug/ml 
A260/A280 = 0. 34/0. 136 = 2. 50 
3.1. 3 PCR amplification: 
Result of the PCR amplification of the first strand cDNA of the EBV 
DNase is shown in fig.4 . The PCR product corresponds to 1. 3 to 1. 4 kb in size 
when compared to DNA fragment of ^X174 digested with Hae IIL There are four 
‘lanes in the agarose gel shown in fig. 4. The one on the left is the ^X174 DNA Hae 
III digest marker. Four bands are visible in fig.4. The bands from upper to lower are 
of 1.353, 1.078，0.872 and 0.603 kb in size. The third lane from the left shows a 
band at about 1.35 kb. This is the PCR product ofthe EBV-specific DNase cDNA 
band. The white area underneath each lane are RNA remnants. The other two lanes 
(second from the left and first one from the right) do not show any PCR product 
probably due insufficient PCR product or cDNA. 
3.1.4 DNA Purification of PCR Product 
The agarose slice after incubation with the gel solubilizer (Pharmacia) at 
60 °C has dissolved in a uniform suspension within 7 mins. Li this step the amount 
of purified cDNA was not quantified. Quantitation of PCR product can be done by 
estimation after electrophoresis the with DNA preparation with known 
\ 
concentration on adjacent lanes. However, this requires a substantial amount of the 
PCR product. To save this DNA preparation for subsequent cloning procedures, 
























































































































































































3.1.5 Cloning ofPCR amplified DNase gene into pUC18 Sma I/BAP 
vector 
The concentration ofthe plasmid DNA preparation was found to be 9.75 
ug/mi. The organization of the cloned pUC18/EBV-DNase plasmid is shown in 
fig.5. The diagram shows that the EBV-specific DNase cDNA is being inserted 
between Hind HI and EcoRI restriction enzyme sites. This is where the N-terminal 
of the p-galactosidase gene is situated. This insertion therefore stopped the 
‘transcription ofthis p-galctosidase gene leading to the loss of a-complementation 
with the host cell. The pUC18 gene also contain an ampicillin resistance gene. 
These help in the selection ofwhite recombinants on LB plate suppemented with 60 
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Fig. 5 Plasmid map ofpUC18/EBV -DNase 
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3.1. 6 Transformation by Electroporation 
The transformation frequency is approximately 30:1 i.e. one white colony among 
40 blue colonies habours the pUC18/EBV DNase insert. Afler electroporation, the 
transformant grown on LB plate supplemented with 60 ugy'ml ampicillin, 2%H>TG 
and 2% X-gal is demonstrated in fig. 6. Two kinds of colonies could be seen. Some 
ofthem are white colonies and the rest are blue colonies. The white colonies do not 
break down X-gal due to the loss ofa-complementation with the host cell because 
‘the EBV-specific DNase cDNA was inserted in the position where the N-terminal 
of the p-galactosidase of the pUC18 plasmid is situated. The host cells which 
habour the C-terminal of the p-galactosidase and will normally undergo a -
i 
！ 
complementation with the pUC18 plasmid which has its N-terminal P_ | 
I 
galactosidase. Those which undergoes a-complementation breaks down X-gal and | 
produce a blue colonies. Those which has the EBV-specific DNase cDNA insert 
will not break down X-gal and form white colonies. The white colonies are the ones 
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Fig.6: A picture showing the recombinant E. opli JM105 on LB plate supplemented with 
ampicillin, X-gal and ffTG on a red background. White colonies were 
recombinants with the EBV-specific DNase insert in the pUC18 plasmid which do 
not undergo a-complementation . Blue colonies were recombinants which did not 
have the EBV-specific DNase insert and undergo a-complementation breaking 
down X-gal and appearing blue. 
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3.1. 7 Extraction ofPlasmid DNA 
The purpose ofthis extraction is a prelude to subsequent digestion by the 
restriction enzymes, EcoRI and Hind III，which flank the EBV-specific DNase 
insert. This is needed to determine whether the white colonies that are picked and 
cultured have the EBV-specific DNase cDNA insert in the pUC18 plasmid and 
whether the insert has the right size as that of the PCR product. 
^ 
3.1. 7.1 Boiling Preparation: 
After the addition of STET and boiling for 40 sec. and centrifugation, the 
bacterial chromosome settle at the bottom ofthe eppendorff tube as a viscous mass. 
The supematant was clear. 
After the chromsomal mass was removed with the addition of sodium 
acetate and isopropanol, a white precipitate settle at the bottom of the eppendorff 
tube after centrifugation. However, after drying at 37°C for 15 min. part of the 
white precipitate became transparent. The size of the precipitate was about twice 
the size of a pinhead. There was no difficulty in suspending the pellet in water. 
. . 
However, when the pellet was overdired, say, more than 30 mins. at 37�C， 
resuspension in water became more difficult. The DNA concentration was found to 
be 9.09 ug/ml. 
\ 
3.1. 8 Plasmid digestion 
The results ofthe digestion is shown in fig. 7. This gel is divided into two 
halves : The upper half and the lower half. The lane to the lefl are the molecular 
, size markers with (j>X174 DNA fragment generated by Hae HI digestion as 
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lanes only. These are the third, fourth and the sixth lanes from the left in the upper 
half of the gel. The insert estimated size of the DNA matches the size of the 
predicted PCR product which is about 1.3 kb in length. Besides the insert, there are 
several bands on the upper parts of the insert. These are interpreted as the pUC18 
plasmid bands ofdifferent conformations or they are from the chromosomal DNAs 































































































































































































































































































































































3.2 DNA sequencing^ig.8-12 are the X-ray fihns ofthe DNA sequencing ofB95_ 
^ ¾ ¾ ! ^ ^ ^ ^ ^ ^ ^ DNase cDNA. Fig.8 is sequenced with primer number 1. 
Primer no.l is situated at the 5，end ofthe polycloning site of the pUC18 plasmid. 
From fig.8 the SmaI site of the pUC18 plasmid can be read. This is followed by 
base no. 1 to base no. 126 ofthe EBV-specific DNase cDNA insert. Fig. 9 is a long 
running gel i.e. a gel which has been electrophoresed for 8 hrs，with primer no.l. 
The purpose ofrunning a long gel is to see the upper bands of the short gel more 
clearly. Fig.9 reads from base 121-378 of the EBV-specific DNase cDNA insert. 
« 
With these two gels ofprimer no. 1，base 1-378 ofthe EBV-specific DNase cDNA 
insert can be read clearly. In fig.lO there are four gels here. This was performed 
using primer no.2-5. These are all short gels, i.e. gels which has been run for 2.5 
hrs. The first gel on the left is run with primer no.2 , the second gel with primer 
no.3 etc. These results were obtained by using primers situated in the inner part of 
the EBV-specific DNase cDNA sequence. This was necessary since there is a limit 
where T7 DNA polymerase can extend the sequence created by primer no.l. The 
DNA sequence deduced from these four gels read from base 319-950 ofthe EBV-
specific DNase cDNA sequence. Fig. 11 is the long gel ofprimer no. 6. Primer no.6 
is situated at the 3'end of the polycloning site where the EBV-specific DNase 
cDNA is inserted. Therefore, primer no.6 is complementary to the EBV-specific 
DNase cDNA sequence. By the use ^f the DNASIS program from the computer, 
one could deduced the complementary sequence extends by primer no.6 to the 5’ to 
3，sequence of the EBV-specific DNase cDNA insert. This gel reads from 943-
1321 ofthe EBV-specific DNase cDNA insert. Fig.l2 is a short gel of primer no.6. 
^ This reads from 1123-1434 ofthe EBV-specific DNase cDNA sequence. Base 1434 
51 
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is the end of the insert. Therefore by utilizing these six primers , the whole 
sequence of the EBV-specific DNase cDNA insert can be deduced. Fig. 13 is a 
sequencing gel of Raji EBV-specific DNase cDNA insert. It utilizes primer no.l for 
the 5' end of the sequence and primer no.6 for the 3' end of the sequence. It 
consists of two gels . the one at the bottom is the sequence of the 5' end while the 
one at the top is the 3' end of the insert. Fig.14 is an enlarged portion of the 3' end I 
of the insert of fig.13. It shows how the gel is read and also shows the difference 
, ·between the B95-8 and the Raji derived EBV -speicifc DNase cDNA inserts .. 
\ 
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Fig.lO DNA sequencing gel(short gel) 
ofB95-8 EBV derived 
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Fig. 11 : DNA sequencing gel(long gel) 
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Fig.l2 DNA sequencing gel(short gel) 
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3.2.1 Comparison of B95-8 EBV-specific DNase gene with gene sequence of 
EBV in GeneBank: 
The following is a comparison of the cloned EBV -specific Dnase gene 
with the EBV gene sequence from the GeneBank. B95CLSEQ is the cloned and 
sequenced B95-8 derived EBV-specific DNase gene on the top. EBV is the DNA 
sequence of the entire Epstein-Barr virus genome obtained from the GeneBank as 
shown at the bottom. Homology is indicated by double dots between the upper and 
. the lower sequence. 
The number of the bases are shown at the top and the bottom of the corresponding 
sequence. The % match is indicated to be 100%. 
FILE NAME B95CLSEQ 
SEQUENCE 1434 BPi 341 Ai 386 C; 396 G; 311 T; 
RANGE 1 - 1434 MODE NORMAL 
CUTOFF 45 KTUP : 4 
Target sequences on data disk 
No. Target file Definition 
OPT 











100.0 1434 5736 
10 20 30 40 50 60 
TTATTCCCCCGTCCACGTCGCCTATGGAGTTGACTCGTCGTCGGCAAAGAGACCAGAGGG 
X:::::::: : ::::::::::::::::::::::::::::. ::::::::::::::::::::: : 
TTATTCCCCCGTCCACGTCGCCTArGGAGTTGACTCGTCGTCGGCAAAGAGACCAGAGGG 
120910 120920 120930 120940 120950 120960 
70 80 90 100 110 12 0 
CACCCATGGCGCGGTGTCAAAAGTATTGTCTGCGTACGCTTTCCAGGAGCCAGCCGCGGT 
................... . ......................................... 
· . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
CACCCATGGCGCGGTGTCAAAAGTATTGTCTGCGTACGCTTTCCAGGAGCCAGCCGCGGT 
120970 120980 120990 - 121000 121010 121020 
130 140 150 160 170 180 
GCTCAAGGTCTTACGGATGACAGAGTCCGGCAGGACCACGGGTGTCACCAGCACCGCCAC 
· ................... \ ..................................... . . 
· .......................................................... . 
GCTCAAGGTCTTACGGATGACAGAGTCCGGCAGGACCACGGGTGTCACCAGCACCGCCAC 
121030 121040 121050 121060 121070 121080 













































· . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
· . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
CCCGGGCTTGCCACCCCCACTGTGGCGGACGTAGTCTCCAACAATTTTGTATTGGAGGAG 
121210 121220 121230 121240 121250 121260 
370 380 390 400 410 420 
CACCTGGTAGAAGTAGTTGTGCCGTGGATTGATGAAGATGTTGACTGGGACCCGGTCTTT 
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : 
CACCTGGTAGAAGTAGTTGTGCCGTGGATTGATGAAGATGTTGACTGGGACCCGGTCTTT 
121270 121280 121290 121300 121310 121320 
430 440 450 460 470 480 
AATACCAATGCGCCCCGCATTTTCGCTTGGGTCCGTCATTACGTAGAGCATAGACTCCAC 
· .......................................................... . 
· .......................................................... . 
AATACCAATGCGCCCCGCATTTTCGCTTGGGTCCGTCATTACGTAGAGCATAGACTCCAC 
121330 121340 121350 121360 121370 121380 
490 500 510 520 530 540 
CCCCCTGTTGGCAGCTAGGCTGTCTGCCACCAGGTCATGACCGGGGCCCAGTTTGCGCTT 
· .......................................................... . 
· .......................................................... . 
CCCCCTGTTGGCAGCTAGGCTGTCTGCCACCAGGTCATGACCGGGGCCCAGTTTGCGCTT 
121390 121400 121410 121420 121430 121440 
550 560 570 580 590 600 
ACGGACATCTTTAAGATTCCAGGCCTCATCCTGCGTCAACAGATAGTCACCCTCCGAGGG 
· .......................................................... . 















: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : 
CAACCGCCCATCCGGGACGTACTCCACGGTAGGACGAGCTATAGAATTGATAAATCTGAT 
121510 121520 121530 121540 121550 121560 
670 680 690 700 710 720 
AAATGACCTCTTGCATGGCCTCTTGTAAAGCGCAGTGTAGGATGGGTAGATGGGGTCAAA 
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : 
AAATGACCTCTTGCATGGCCTCTTGTAAAGCGCAGTGTAGGATGGGTAGATGGGGTCAAA 
121570 121580 121590 121600 121610 121620 
730 740 750 760 770 780 
TTCTGACTTGGAAAAGAGGTACTTGAAGCGGCACTTAATCTCATAAATGCAGCTCCGGTC 
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : 
TTCTGACTTGGAAAAGAGGTACTTGAAGCGGCACTTAATCTCATAAATGCAGCTCCGGTC 
121630 12164q 121650' 121660 121670 121680 
790 800 810 820 830 840 
GGTGAACAGTATAAAGTCTCCCTGTGACTCCACATTGACGCAAAGATCCAGAGACACCCC 
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : 
GGTGAACAGTATAAAGTCTCCCTGTGACTCCACATTGACGCAAAGATCCAGAGACACCCC 
121690 121700 121710 121720 121730 121740 




121750 121760 121770 121780 121790 121800 
60 
920 930 940 950 960 
B9SCLSEQ GCA_^TTAC:AOACAATGTC:_A_aT_ACA_AGGeCAAAGae<^,<^ 
咖 ：EFEFE^^—-，= 
o7r^  980 990 1000 1010 102 
33SCLSEQ AGGTCCCrcLAGTAGTGATTTGTGGAGATGGGAGCTGGCTCAAACACCTTGGTGGGTCC 
， v - = ^ 
,,3CLSEQ ATTCTTil=TGGAGi=GC:rrGG=L^AAATTATGec:ATTTa3eAA_GTC^eC^A 
- ™ « 
二 1100 1110 1120 1130 1140 
,,3CLSEQ CATCAG:=TCAGACTGCCCCCTGGTCATGGACTCCACGTACGAGCAGAGAACAGTCCT 
- ™ ^ 
llso 1160 1170 1180 1190 1200 
33SCLSEQ CTGCTCGTCGGTGGCCTCCTGTAGCCCCCAGTAAATGGATTTCAGGGAGGGACCGTCCTT 
咖 c ； ； ™ ^ 
lflO 1220 1230 1240 1250 1260 
B 9 5 C L S E Q G C T G T C A T T C T C T T G G A C T A A C G A G G A G A C A A A G T C A C A G A A G C C A G，， , ( ^ ( ^” , ( ^， 
T ;^ <^i^ S^i^ (j:i:(j:i4(^ A^ C^GAGGAGACAAAGTCACAGAAGCCAGTTTCACCAGAGAA 
E B V G C T G T C A T T C T C T 丄之^ ,^2130 122140 1 2 2 1 5 0 1 2 2 1 6 0 
1270 1280 1290 1300 1310 1320 
B 9 5 C L S E Q cTCTTGTATTTGTTTACAGAGGCAATAGAGATAGACAAAGCGCATGGCCGGCA^^C ^， , ( ^ ( ^ 
妳, GSi^ <ii>i>i4(^ i4i"l(i:AGAGGCAATAGAGATAGACAAAGCGCATGGCCGGCATCTGAGG 
E B V C T C T T G T A T ^^^^^^ 122190 122200 1 2 2 2 1 0 122220 
1330 . 1340 1350 1360 1370 1380 
B 9 5 C L S E Q . T G G A C G G T C A A G G T T A C G G A C A A A G G C C T C A G T C T C C G G A C T G C G G A G G A A G C G G G C ^ 
.而 ^^ ;^=GGACAAAGGCCTCAGTCTCCGGACTGCGGAGGAAGCGGGCA^ 
E B V 122230 122240 1 2 2 2 5 0 , 122260 1 2 2 2 7 0 122280 
1390 1400 1410 1420 1430 
B 9 5 C L S E Q C G T G T A G G A G G T C A T C T C C T C C A T G G G A T C C T C G A G C T C A T C C A C G T C G G C C A T 
^ , , , <j;;<i^<i>^;^(jrC^^TC"CrcrTC:CATGGGATCC:T:C:GAGC:TCATCCACGTCGGCCAT 
E B V 122290 1 2 2 3 0 0� 122310 122320 1 2 2 3 3 0 
\ 
The results showed that the cloning procedure ofB95-8 derived EBV-





3 .. 2.2 Comparison of5' end of Raji & B95-8 EBV derived EBV-specific DNase gene 
The 5'end of the Raji EBV DNase gene was compared with that of the B95-8 
EBV -specific DNase gene from the GeneBank to see if there is any base difference 
between the Raji derived and the B95-8 derived EBV ... specific DNase gene sequence. 
FILE NAME RJCLSEQ 
Target sequences on data disk 
No. Target file Definition Match% Over. INIT OPT 
1 EBV 100.0 109 436 436 




122230 122240 122250 122260 122270 122280 




122290 122300 122310 122320 
The diagram is a homology comparison between the 5' end of the Raji cloned EBV 
DNase sequence with that of the EBV DNA sequence from the GeneBank. The 
results showed that the 5' end of the Raji EBV DNase gene sequence had 100% 
homology with the B95-8 EBV DNase sequence.- This is particularly important 
since amino acid 20-28 of the EBV -~ecific DNase is the functional domain of the 
protein. This comparison indicates that the functional domain of B95-8 derived and 
Raji derived EBV -specific DNase is conserved. 
62 
-.0--
- ' , ' 




Raji 3' end 
sequences on data disk 
No. Target file Definition 
1 EBV 
Match% Over. INIT OPT 
97.1 140 536 536 
10 20 30 40 50 60 
Raji 3'end TTGACTCGTCGTCGGCAAAGAGACCAGAGGGCACCCGTGGCGCGGTGTCAAAAGTGTTGT 
X::::::::::::::::::::::::::::::::::: :::::::::::::::::: :::: 
EBV TTGACTCGTCGTCGGCAAAGAGACCAGAGGGCACCCATGGCGCGGTGTCAAAAGTATTGT 
120940 120950 120960 120970 120980 120990 
70 80 90 100 110 120 
Raji 3' end CTGCGTACGCTTTCCAGGAGCCGGCCGCGGTGTTCAAGGTCTTACGGATGACAGAGTCCG 
. . . . . . . . . . . . . . . . . . . . .. ......... . ......................... . 
. . . . . . . . . . . . . . . . . . . . .. ......... .......................... . 
EBV CTGCGTACGCTTTCCAGGAGCCAGCCGCGGTGCTCAAGGTCTTACGGATGACAGAGTCCG 
121000 121010 121020 121030 121040 121050 
130 140 





The diagram was a homology plot of the 3' end of the Raji EBV DNase gene with 
that from the B95-8 EBV 3' DNase gene. There were four base changes observed 
as shown by the absence of the homology double dots in the graphics. These base 
changes were (from B95-8 to Raji): A to a G at position 121019, 120992 and 
120973 of the EBV genome. The fourth one was a C to a T change at 121029 of 
the EBV genome. The match was only 97. 1 %. That there are base changes at the 
, 
3' end may have implications if these changes result in amino acid sequence 
changes which will affect the conformation of the EBV-specific DNase from B95-8 









3..2.4 Amino acid sequence homology between B95-8 & 卿 EBV-specific 
DNase 
The d iagram showed the amino ac id homology between the 5，end of the Raji 
EBV-specific DNase sequence and that of the B95-8 EBV-specific DNase 
sequence. The amino acids are all in one letter symbol. Double dots between the 
two sequence represents homology ： 
FILE NAME ： B95DNASE • 
Target ： sequences on data disk 
. . Match% Over. 
No. Target file Definition 
INIT OPT 100.0 36 
1 RJDNASE 
1 7 8 1 7 8 10 2 0 30 4 0 
EBVDNASE DELEDPMEEMTSYTFARFLRSPETEAFWNLDRPPQ 
^ _rmrASE DELEDPMEEMTSYTFARFLRSPETEAFVRNLDRPPQ 
R J D N A S E 10 2 0 30 4 0 
As expected , the N-terminal amino acid sequence between the B95-8 
derived and the Raji derived EBV-specific DNases are the same since their DNA 
sequence shows 100% homology. Amino acid 20-28 is the functional domain ofthe 
EBV-specific DNase. Any changes in ammo acid residues in this site will decrease 




.1 ‘ ‘ 
3.2.5 Amino acid sequence comparison between the 3' end of the B95-8 EBV 
DNase protein with that of the Raji EBV DNase protein. 
FILE NAME 
Target 
RAJI 3' SEQUENCE 
sequences on data disk 
46 AA 








10 20 30 40 
VTPVVLPDSVIRKTLNTAAGSWKAYADNTFDTAPRVPSGLFADDES 
X: : : : : : : : : : : : : : . : : : : : : : : : : : : : : : : : : . : : : : : : : : : :X 
VTPVVLPDSVIRKTLSTAAGSWKAYADNTFDTAPWVPSGLFADDES 
430 440 450 460 
As observed from the comparison, there were two amino acid changes. 
The first one was at residue 438 of the B95-8 EBV DNase, it is a change from 
serine to asparigine and one at residue 457 of the B95-8 EBV DNase, the change is 
from a tryptophan to an arginine residue. The first change is from a polar to another 
polar amino acid. The second change, however, is a change from a non-polar amino 
acid in the B95-8 derived DNase to a polar amino acid in the Raji derived DNase. 
The latter change may alter the conformation of the protein at this site and if this is 
. an important immunodominant site, the two EBV-specific DNases from B95-8 and 
Raji cell lines may be different. The difference in hydrophilicity is highlighted in 









FILE NAME : B95.AMI 
HYDROPHOBICITY INDEX TABLE FILE: HOPP.THR 




2 + I 
I 
1 + I 
* ** * I * * * * 
o +-*------*+-*---*---+--------*+------*--+--*--*-*-+-----
* 1* 1 * *** * * * 1** 1* 
-1 + 1 1 1 1 
* ** *1 1 * 1 
-2 + * * * * 1 *1 
* *1 * 
-3 +---------+---------+---------+*--------+---*-----+-----
o 10 20 30 40 50 
HYDROPHOBIC DN S SSEQ P PDS RK S GS K DN D P PSG DDES 
HYDROPHILIC A I VT VVL VI TL TAA W AYA TF TA WV LFA 
The underlined area was a hydrophobic area. 




2 + 1 
I 
1 + I 
1 * ** * 1 * * * 
o +-*------*+-*---*---+----*---*+------*--+--*--*-*-+-----
1 * I * I * *** * * * I ** 1* 
-1 + I 1 I I 
* ** * I I * I 
-2 + * 1 * * * I *1 
I * * I * 
-3 +---------+-----~---+---------+*--------+---------+-----
o 10 20 30 40 50 
HYDROPHOBIC DN S SSEQ P PDS RK N GS K DN D PR PSG DDES 
HYDROPHILIC A I VT VVL VI TL TAA W AYA TF TA V LFA 
The underlined area was a hydrophilic area. 
66 
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3.3 Epitope Mapping 
A hydrophilicity plot ofthe cloned B95-8 derived EBV-specific DNase is 
shown in the following figure, ][n this plot, each amino acid is assigned a score. The 
higher the score, the more hydrophilic the amino acid is. A negative score means 
the amino acid is hydrophobic. The score is an averaged score amount seven 
adjacent amino acids. Those regions above zero are hydrophilic and those below 
zero are hydrophobic. The use of this plot is used to identify hydrophilic 
ixnmunodominant regions. The theory is that the hydrophilic regions are usually 
« 
situated on the outside of the molecule since they can mix with water. Those 
regions that are hydrophobic cannot mix with water to give a maximum entropy. 
Therefore, they are more likely to be buried inside the protein molecule. Since the 
hydrophilic regions are on the outside ofthe protein, they are more likely to induce 
antibody formation towards them. Therefore, hydrophilic regions are chosen to be 
candidates for immunodominant regions. 
FILE NAME : B95CLSEQ.AMI 
(FROM 1 TO 478) 
THRESHOLD LINE : 0.00 
Index + … 十 + + 
M T j 丨 - I 丨 ！ 2 + I I 
I * **•* 丨 丨 1 I 
1 ! * * *1 I M I ** I 
1 + * I > ^ 山“ 1 * * •** 
卜 * * I* * * I* *** I I I 
‘ • •••_• * - * * * * - * + + - - * " * 女 
0 I * ** , I * … *** *l I * * 1 I I … * 丨 I ! I * I I I I * I I - 2 ； I I I I I 
,1 ； + + z _3 + 10 20 30 40 50 60 







1 1 1 I 
2 + 1 ** 1 1 I 
1 ** 1 * 1 I 
1 + 1 * * 1 1 ** *** * 1 
1* 1** * * * ****1* I 
o +-*------**---------+*--------+------**-+----*----+-*-*----** 
***** 1 1 * **1 *1**** * * ** 
-1 + * I 1 *** * 1 * * 
I 1 * 1 
-2 + 1 1 1 
1 1 1 
-3 +---------+---------+---------+---------+---------+---------+ 
60 70 80 90 100 110 120 
HYDROPHILIC G SSLVQENDSKDG GLQEATDE YVESMTRG S D 




2 + 1 
1 ** 
1 + 1 * * ** 
** 1* * * ** 
o +--*-*****+*-***--*****-**----+---------*-------*-+---**-**-+ 
1 * * * * * * * * * * * * * * 1 1°* * * 
-1 + *1* *** * 1 1 * 
1 1 1 
-2 + 1 1 I 
1 1 1 
-3 +---------+---------+---------+---------+---------+---------+ 
120 130 140 150 160 170 18~ 
HYDROPHILIC R G S K STIK GPTK E AFGLRCED VK CK CGD 




3 ； ； 丨 丨 
. 1 1 I 1 I 
1 ！ • I * I 
1 + … *丨 * I * * I 
1 丨 丨 • “ ‘ .__****.**--*-**--+***---**-+ 0 +** **** + -.*-**---4- * *** •* 
1 *** *l ** ****** * * I I 
I * I 1** 1 
- 1 + *** I * I 
- 2 ; i I 1 丨 丨 _^  
-3 + , in 220 230 240 
• 190 _ D W ^ E LFTD IYEIK KY FSK 
HYDROPHILIC AS nTP^x,cT Tr SOGDFI RSC CRF L SEFD 
HYDROPHOBIC ANRQFGFMISPTDGIFGVSL LC SQGDFI 
« 
Index + 
3 ; - _ 1 I * I 
1 I I 1 I 
2 + I I * * * * I 
I 卜 * * I I * 叫 
1 + t * “ * * *• • 叫 * *• * * 
I • • • ^ I I 
� i … … 二 * :-•**-**-*•-* 广 * * * * - * - 广 j 
1 * ! •**•;* • 1 * 丨 1 
- 1 + * * * * I 1 I 1 
1 1 I I 
-2 + I I I 
1 1 ； 
-3 ; ; r ' " 260 270 280 290 300 
2^0 T=&KRPCK N IAR TVEYVPDGRLPS LLTQDE WNLKDVRKR 
HYDROPHILIC TALYKRPCK EGDY A 
HYDROPHOBIC PIYPSY RSFIRFI S i：^ 
Index + + 
： 厂 — - 厂 — 丁 - … 1 丨 I 丨 
I 1 1 
I I ***I ** * * I I I 
M* * 丨 * … I ** ： ？ — 二 丄 … 一 丄 … … 」 
‘ 0 — * * * * - * - * * - * * ——*-- + ——、 ；“ 丨 * * * … * * 
I * I *** *� 丨 , 
I 卜 * I * * I • * * 
-1 + I 1 * I *••* 
1 1 I I 
- ” 1 j 1 I i ； + 
二 ;;0 320 330 340 350 360 l„ T, nur. ADS AANR VMTDPSE AGRIGIKD .�HYDROPHILIC K GHD ADS AAJNK RVPVNIFINPRHNYFYQVLL z HYDROPHOBIC LGP LV L GVESMLY M 





3 . 厂 … … ! � 1 I 
1 1 I 
2 ; • * I I 
1 i * 一 * * 
** 1** * **** * 1 I 1 " _• . *•** + -**--***-** 
0 + * - * * * - - * * + 1 ：： T ** ** *| **** I 
I * I ** I I * * * * 
- 1 ； * * I 
I I 1 * I 
-2 ； 1 I I 
I j ： I 
_3 + 二 400 410 420 
360 370 380 ^^° oSD LLD 
HYDROPHILIC Q VGDVRHSGGGKPGRD TAFFRKRSpLDpATCTL L ASVEIPVA 
HYDROPHOBIC YKI Y CSPRVN1V 
• 
Index 
3 + ； ； j I 
I I 
2 + I j I * I 
I j I I * * * I 
1 ； *； ** * - l** * I … 
1 丨 二 * * * * + * * * * ——* 0 — - - - * - - • - + • * - - * - - - ” - - * * - : * - - [ * * *** I * ** I *** |** * 丨* * I 丨 
I I I * * * * I 
- 1 +•*• 丨 * 1 
I I I 
-2 I I I I 
1 I + + + 
- 二 — - 一 £ 戰 4 4 � 二 。 = G L ^ / 7 � 靜 
‘ = O B " c V . ^ " ^ - S . ^ C S W . NTFDTAPWVP • 讀 
\ 
z . 
• Vt-:7'v- ;-_.—,...' 
70 
3.3.1 Table 2: Amino acid key 
Amino acid symbol Amino acid 
A Alanine 
C Cysteine 
D Aspartic acid 





















From this plot, thirteen hydrophilic regions are chosen as candidates of 
immunological important epitopes. To qualify as an immunodominant candidate, 
the region not only has to be hydrophilic, but it also has to be of at least eight 
amino acids long in order to elicit an immune response. Therefore, hydrophilic 
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t)le 3: Amino acid sequence of peptides ,ts' sera. 
f 
hQ following table list the amino acid sequence of peptides chosen : patients' 
ito the criteria discussed above. They are all in one letter symbol. An s sufficient 
j 
-• ': 
(eptide known to react with NPC sera was used as a positive control. The aeasured at 
•f candidates are those which are hydrophilic and longer in length. 
. Peptide amino acid sequence and amino acid Patient 5 
positions 0.075 
: MADVDELEDPMEE (1-13) 0.066 
FARFLRSPETEA (19-30) 0. 096 
SSLVQENDSKDGP (70-82) ‘ 0.051 
GLQEATDEQ (90-98) 0. 046 
‘ VESMTRGQ(106-113) 0.056 
~ AFGLRCEDTVKD (160-171) 0.078 
TALYKRPCKR (247-256) 0. 021 
• VEYVPDGRLPSE (270-281) 0.032 
“ WNLKDVRKRKLG (292-303) 0.098 
ADSLAANR (310-317) 0. 101 
“ VMTDPSEN (325-332) ~~ 0.056 
i AGRIGKD (333-340) 0.057 
\ 
I TAFFRKRSPLD (389-399) 0.079 
3onSd From EBNA1 “ 0. 111 — 
； i I 
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CHAPTER 4 Discussions 
4.1 Overall Strategy for cloning of EBV -specific DNase gene 
Two cell lines were used in the molecular cloning of the EBV DNase. 
These were B95-8 and Raji cell lines. The overall strategy in the c1.oning process 
was to extract the mRNA from these cell lines and used the enzyme reverse 
transcriptase to convert these mRNA to cDNAs. To select and to amplify the EBV-
. · specific cDNA among the total cellular cDNA created by reverse transcription, 
specific primers for the EBV DNase cDNA gene were used in a peR reaction. To 
determine whether the PCR had worked, the size of the amplified cDNA was 
analyzed by agarose gel electrophoresis. They were then extracted from the gel and 
inserted into the pUC 18 plasmid, after blunting and kinasing, at the site where the 
N-teriminal beta-galactosidase gene was situated. This resulted in the loss of 
production of the N-terminal beta-galactosidase and the loss of alpha-
complementation with the host cell JM 1 05 which had the C-terminal of the beta-
galactosidase. The plasmid was put into the host cell E. coli JMI05 by 
electroporation .. The colonies were selected by the lack of alpha complementation 
onto a LB with 60 ug/ml of ampicillin plate supplemented with 2% X-gal and 2% 
IPTG. The lack of alpha complementation meant that the E. coli host cell was 
carrying the pUC18 plasmid with th~ EBV DNase cDNA insert and resulted in a 
white colony on the plate. Host cells which had alpha-complementation did not 
have the EBV cDNA insert would appear as blue colonies on the LB plate . 
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4.2 Significance ofEBV-specific DNase as marker for NPC 
Since EBV-specific DNase had been shown to be a good marker for the 
diagnosis and prognosis of NPC, the development of a quantitative test for 
measurement of anti~EBV specific DNase was much needed. Currently, there were 
two disadvantages of quantifying EBV -specific DNase antibodies in human sera. 
These disadvantages were that the anti-EBV DNase assay for NPC were being 
.&'. d b h 1"" 146 149 150 151 hi h "d h f perlonne y t e enzyme neutra Izatlon tests ' , , w c requIre t e use 0 
. radioisotopes. This was not very suitable for use in a routine diagnostic laboratory. 
I dd"" h d d" d C h" 146149 150 151 Th" n a Itlon, t ere were no stan ar Ize reagents lor t IS test ' , , " IS res 
ulted in variation of the assay between different laboratories" To sunnount these 
obstacles, an ELISA assay for measurement of anti-EBV DNase is needed. Two 
approaches were adopted. One was to use synthetic pep tides as immunodominant 
epitopes of the EBV -specific DNase protein. Hydrophilicity plot was studied with 
the EBV DNase amino acid sequence as deduced from the DNA sequence. This 
strategy relied on the fact that the hydrophilic region of a protein was usually 
situated on the outside of the protein molecule, hence they are exposed to the 
surrounding environment and were postulated as potential immunologically 
important epitopes. The other approach was to clone and express the whole native 
EBV -specific DNase protein to be used as antigen for the detection of anti-EBV 
specific DNase antibodies in an ELIS~. 
4.3 Characterization of EBV -specific DNase 
EBV -specific DNase extracted from lymphoblastoid cell line has a higher 
molecular weight than that expressed in E. coli. 160 Therefore, this had to be studied 
further to see whether such modification might have an effect on the 
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immunogenecity of the EBV DNase protein. Besides this, additional investigation 
160 has shown that the EBV DNase is a methanol sensitive nuclear protein, hence 
the classical definition of EA-D and EA-R ^" have to be reviewed more fully by 
specific sera such as those raised in recombinant EBV DNase. 
The EBV-specific DNase have been further investigated in another study 
164. In a report by Su-Fang Lin and associates in 1995，the ends of linear dsDNA 
were labelled using the Klenow fragment at the 3’ end and using T4 polynucleotide 
‘k inase at the 5’ end. A complete digestion of these labelled DNAs by EBV DNase 
was then done. Result showed that the EBV DNase digestion product were 5’ 
monophosphate nucleosides^^^. In addition, EBV DNase was shown to be 
processive for dsDNA but distributive for ssDNA ^^ ^ and that EBV DNase prefers a 
5’ to 3，digestion direction than the 3’ to 5' direction^^^. 
4.4 Molecular Cloning ofPCR amplified DNase gene into pUC18 Sma I/BAP 
vector 
4.4,1 Cell Culture 
The use of 20% fetal calf serum in the culture of B-95-8 cells provides more 
growth factors for the cells to prolifeate, thus an increased in the number of cells 
per ml was observed. It was also found that changing the medium once every two 
days resulted in more cells per ml. However, changing medium more frequently 
\ 
than every two days will lead to less cells per ml. Addition of n-butyrate did not res 
ulted in increased cell number. 
][nitially, n-butyrate was not used in the culture ofB95-8 cells. The yield of EBV-
specific DNase mRNA from the B95-8 cells increased after n-butyrate addition as 
z. 
—— evidenced by the detection of specific bands after PCR amplification. Ln the present 
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project we used mRNA as our starting material to create a double-stranded cDNA. 
The reason for using mRNA and not DNA coding for the EBV-DNase gene directly 
was to avoid the presence ofintrons in the EBV DNase gene. The use ofmRNA to 
create the cDNA ensure that the correctly processed DNase protein is cloned and 
expressed with full function and antigenic properties. 
4.4.2 PCR amplification 
During PCR amplification of the cDNA, the size of the product matches 
‘ w i t h the size of the expected cDNA product and that the primers used have little 
homology with other viruses. In addition, repeated PCR amplification to create the 
2nd strand DNA always results in the appearance of a band ofthe correct size. 
4.4.3 Blunting, kinasing and ligation ofEBV-specific DNase cDNA into pUC18 
vector 
Before using the purified EBV-DNase double-stranded cDNA for ligation 
into the plasmid pUC18 it is necessary to carry out blunting and kinasing of the 
purified cDNA. It is a known fact that many of the thermostable enzymes like Taq 
polymerase used in PCR produce protruding 3’ adenosine residue in the PCR 
product. This 3,A has to be removed first. This is done by the 3，-5’ exonuclease 
activity of the Klenow fragment ofE. coli DNA polymerase L The 5，end of the 
PCR fragment is then phosphorylated by T4 polynucleotide kinase. The resulting 
\ 
product is purified by phenol -chloroform extraction. After that, the aqueous phase 
TTV>f 
is passed through a Sephacryl S-200 resin minicolunm for purification. 
Ln the process of phenoVchloroform purification afler blunting and 
kinasing the interface between the aqueous and organic phase contains much 
z 
protein due to the presence of enzymes in the blunting and kinasing reactions. 
.-'，••.... 
•-： ---^-Kyr-',-.^-^ • 
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Hence, the pipetting of the aqueous phase have to be very carefully done so as to 
exclude the protein in the interface. To achieve this, some of the aqueous phase was 
excluded to avoid contamination from the protein interface. 
During ligation, phosphodiester bond was then formed between a 
dephosphorylated pUC18 SmafBAP vector and the EBV DNase insert catalyzed by 
Bateriophage T4 ligase. An equal molar ratio of insert ends to vector ends is used 
for optimal ligation efficiency. The insert is flanked by EcoRI and HindIII 
• restriction site on the plasmid vector. 
In the ligation reaction between the plasmid and the pUC18 vector, there 
are formation of phosphodiester bond between the 5'phosphate group ofthe insert 
and the 3，hydroxly group ofthe vector DNA. This is a biomolec ular events. The 
rate ofthis formation depends on the concentration of the termini on the insert and 
the vector. 
There are three possibilities on the ligation reaction. The first one is that 
the pUC18 vector will recirularize to form a closed circle and ligation will fail. This 
happens when the insert and the pUC18 vector is at a low concentration so that the 
insert and the vector seldom encounters one another for the ligation to proceed. The 
second possibility is that the recombimnant plasmid will have several inserts in it. 
This happens when the insert is at a much higher concentration than the vector. The 
\ 
third possibility is that the vector will have only one insert in it. These three 
possibilities are dictated by two parameters, j and i. j represents the likelihood that 
the two ends of the vector will encounter each other and becomes circularized, j is 
inversely proportional to the length of the DNA molecule. This is reasonable since z : 
the shorter the length of the vector the more likelihood that the two ends of the -.-':.^_''^Li.'tf^''^r .' ‘• -i .-'，‘-:'，:.-
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molecule will met and ligate to each other, j is also affected by the ionic strength of 
the solution the vector is in since ionic strength affects the rigidity of the DNA 
molecule. The higher the ionic strength, the more rigid is the DNA molecule and 
vice versa, i is a measurement of all the effective concentration of all compatible 
termini in solution. 
If i=j, then there is an equal chance that both recircularized molecule and 
recombinant will be formed at equal frequency. Ifj>i, then recircularized molecule 
. w i l l be favoured. Ifj<i, then formation of recombinants will be favoured. Usually, i 
should be two to three fold more than j for ligation reaction. This favoured the 
formation of the recombinant molecule containing only one insert. If i is too much 
overj, then the recombinant molecule will have more than one insert. 
Before the ligation procedure is carried out, the concentration of the PCR 
product was estimated by a spectrophotometer and adjusted to be equal to the 
pUC18 vector. Therefore i=j in this sense. 
4.4.4 Transformation by Electroporation 
After ligation, eletroporation is carried out. It is believed that when 
bacterial cell is subject to high electrical field, its cell wall becomes porous and will 
let any DNA in the medium to enter the cell. Electroporation is usually carried out 
in the cold (0-4°C) since the efficiency of the tmasformation drops about 100-fold 
\ . • . 
when it is carried out at room temperature. Li addition，if too much ions were 
present in the electroporation cell, the cell will likely to explode due to the 
increased conductance resulting in temperature change. 
z' 
.-.:•. _• ； :->.t .1 
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4.4.5 Restriction enzyme digestion ofpUC18/EBV-DNase plasmid 
The success of the ligation and transformation is determined by plasmid 
digestion with EcoRI and Hind III which flanks the polycloning site of the pUC18 
plasmid. 
The digestion was carried out for one hour. It could be extended up to 
three hours afterwhich EcoRI cut randomly, this results in a smear on the 1% 
.agarose gel. Therefore the digestion was carried out for one hour. The insert after 
digestion has the same size as the PCR cDNA. This establishes the success of the 
ligation and transformation procedure. Sometimes after plasmid digestion, there 
were more than two bands on top of the insert band. These might represents 
different conformation of the pUC18 plasmid which would be closed circular, 
superhelically coiled ,or linear form. However, this might also be due to some of 
the chromosomal DNA being left behind after the boiling preparation. The upper 
bands were the pUC18 vector band and some of the left over chromosomal DNA. 
The band at 1.3kb ,which was at the upper most band of PhiX174 Hae HI of 
molecular size of 1.353kb, was the DNase cDNA insert band. The latter has the 
same size as the PCR product of the DNase cDNA. 
For electroporation, the volume of the plasmid has to be limited to 1 ul. 
The addition ofmore plasmid solution results in bursting of the electroporation cell 
during electroporation due to increased conductance. 
4. 5 DNA Sequencing 
During DNA sequencing, additional primers, besides the forward primer at 
,• 
the 5'end and the reverse primer at the 3'end, were used to cover up the whole of ----. r:.:.-� 
. ^ “ • r-j^if^ ••,--
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the DNA sequence. This is necessary because there is a limit in which T7 can 
progress from the forward and reverse primers. Hence, one has to cover up the 
sequence in the middle of the DNA sequence by starting the process of sequencing 
in the middle ofthe DNA sequence. 
From the determined DNA sequence, the B95-8 EBV-specific DNase gene 
sequence matches with that from the GeneBank. The important point in the 
comparison of the Raji and B95-8 EBV-specific DNase amino acid sequence shows 
. t h a t the EBV-specific DNase gene is conserved at the N-terminal end of the EBV-
specific DNase. This is particularly important since amino acid 20-28 is the 
functional domain of DNase i. e. the active site of the EBV-specific DNase molec 
ule. At the C-terminal end, the one amino acid difference which changed a 
hydrophobic region in B95-8 to a hydrophilic region of the Raji EBV-specific 
DNase implied that in this region, the immunogenecity between the two sorces of 
EBV-specific DNase protein may be different. 
In some regions of the sequencing gels, 'ghost' bands appear in three of 
the four lanes and this is due to the premature termination of the T7 polymerase, or 
due to secondary structure ofthe template. Li such cases，we will take the strongest 
band as the correct reading of the nucleotide. 
With this clone at hand, one could theoretically transfer the insert into an 
expression vector by enzyme digestion to obtain the insert and ligation into the 
expression vector. From it, DNase gene product could be expressed and then 
purified by salt precipitation and colunm chromatography. Its purity can also be 
monitored by DNase assay using radiolabelled DNA as the substrate. It can then be 
.' 
used in a variety of ways. One of which is to serve as an antigen in an ELISA for 
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the detection of EBV DNase antibodies for the screening of high risk group of 
developing NPC or for diagnostic and prognostic purposes. 
4. 6 Epitope mapping 
The peptides were chosen according to the hydrophilic regions in the 
hydrophilicity plot of the EBV-specific DNase sequence. However, they had to be 
at least 8 amino residues long for them to be immunogenic. Peptides shorter than 8 
amino acid residues were not chosen. The results showed that none of the peptides 
. s t a n d out as an important immunodominant epitope. This suggested that all the 
epitopes of the EBV-specific DNase may be conformational or that antibodies from 
patients with NPC did not react with linear epitopes as evidenced by the fact that 
the positive control from EBNA 1 did not have appreciable absorbance in the 
ELISA assay. It may also be that the peptides were not adhering to the microtitire 
wells and a carrier protein of some sort may have to be used to allow for the 
attachment of the peptides to the microtitire wells. In addition, the use of a single 
parameter, namely hydrophilicity may not be enough to predict immunodominant 
epitopes. Other parameters, such as the beta-tums or random coils of the secondary 
structure of the EBV-specific DNase protein have to be taken into account. 
That the epitopes might all be conformational was not surprising since 
EBV-specific DNase was a functional protein and it was intracellular and not a 
\ 
surface protein. Although we were unable to locate linear epitope on the EBV-
specific DNase molecule, there were several articles supporting that this approach 
may work. One was from Anderson in the study of a epitopes of a 65kDa proteins 
178 
of Mycobacterium leprare . In this paper the sites which bind to monoclonal 
.•‘ 
antibodies raised against this bacteria are all on the outside of the protein molecule. 
83 
Another paper written by Don Dailey ^^^also pointed to the fact that the 
immunodominant epitopes of Trichomonas vaginalis were on a hydrophilic area 
near the C-terminal area of the protein. If the EBV DNase molecule had no linear 
epitopes or that patients' antibodies did not react with linear epitopes, whole native 
DNase protein may have to be used as the antigen source. This was the reason for 
initiation of the cloning process in order to obtain whole native EBV-speciflc 
DNase molecule. 
. Our results also showed that different sources of EBV-specific DNase 
might differ in amino acid sequence but their functional domain might remain 
conserved. Because of these facts, different sources of EBV-specific DNase might 
differ antigenically. Therefore, in order to evaluate the efficacy of using EBV -
specific DNase for screening , diagnostic or prognostic purpose, different sources 
of EBV-specific DNase have to be examined in parallel in order to determine the 
one source with the suitable sensitivity and specificity for the above mentioned 
purposes. 
Now that a clone of the EBV DNase was at hand，the next step would be 
to express this clone by inserting the EBV DNase cDNA into an expression vector. 
In addition, different sources of EBV-specific DNase, such as those from P3HR-1 
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